Nipro Corporation Share Price OTC Markets

Stocks

NPRRF

JP3673600007

Medical Equipment, Supplies & Distribution

OTC Markets Traded
Market Closed - OTC Markets 11:37:10 04/03/2026 pm IST 5-day change 1st Jan Change
9.960 USD +2.79% Intraday chart for Nipro Corporation -.--% +21.02%
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Nipro Corporation

Market Cap 27TCr 166.57Cr 145.23Cr 134.51Cr 125.92Cr 236.15Cr 16TCr 237.58Cr 1.6TCr 618.42Cr 7.74TCr 625.25Cr 611.84Cr P/E 2026
18.7x
P/E 2027 * 20.3x
Enterprise Value 76TCr 473.77Cr 413.08Cr 382.58Cr 358.14Cr 671.68Cr 45TCr 675.74Cr 4.54TCr 1.76TCr 22TCr 1.78TCr 1.74TCr EV / Sales 2026
0.38x
EV / Sales 2027 * 1.12x
Free-Float
87.38%
Yield 2026
1.87%
Yield 2027 * 2.02%
12/05 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
12/05 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
01/05 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
11/03 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
09/02 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
24/12 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
10/11 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
10/25/10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
09/25/09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
13/25/13 Jefferies Adjusts Nipro's Price Target to 1,300 Yen from 1,400 Yen, Keeps at Hold MT
12/25/12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2025 and Fiscal Year Ending March 31, 2026 CI
12/25/12 Nipro Corporation Announces Dividend for the Year Ended March 31, 2025, Effective June 27, 2025; Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026 CI
12/25/12 Nipro Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026 CI
1 day+2.79%
Current month+21.02%
Current year+21.02%
3 years 8.23
Extreme 8.23
9.96
5 years 8.23
Extreme 8.23
9.96
10 years 8.23
Extreme 8.23
9.96
Manager TitleAgeSince
President 58 26/06/2025
Chief Administrative Officer 57 26/06/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 81 26/06/2025
Director/Board Member 53 01/06/2009
Director/Board Member 57 01/06/2015
Change 5-day change 1-year change 3-year change Capi.($)
+2.79%-.--% - - 166.57Cr
-0.10%+0.26%-33.52%-17.14% 15TCr
+1.54%-1.07%-8.11%-10.79% 10TCr
-4.45%+3.12%+61.36%+57.49% 5.65TCr
-1.90%-3.49%-7.43%+47.34% 5.29TCr
+1.67%-1.55%-14.51%-43.86% 3.97TCr
-1.32%-1.83% - - 3.04TCr
+1.74%-3.85%-9.41%-44.24% 2.8TCr
+1.35%-0.26%+51.96%-10.42% 2.32TCr
-1.53%+1.14%-15.21%-5.72% 2.03TCr
Average -0.02%-1.30%+3.14%-3.42% 5.63TCr
Weighted average by Cap. -0.26%-1.24%-6.00%-2.77%

Financials

2026 2027 *
Net sales 66TCr 410.2Cr 357.65Cr 331.24Cr 310.08Cr 581.54Cr 39TCr 585.06Cr 3.93TCr 1.52TCr 19TCr 1.54TCr 1.51TCr 70TCr 431.49Cr 376.22Cr 348.44Cr 326.18Cr 611.73Cr 41TCr 615.43Cr 4.13TCr 1.6TCr 20TCr 1.62TCr 1.58TCr
Net income 1.46TCr 9.08Cr 7.92Cr 7.34Cr 6.87Cr 13Cr 857.09Cr 13Cr 87Cr 34Cr 421.87Cr 34Cr 33Cr 1.37TCr 8.53Cr 7.43Cr 6.88Cr 6.45Cr 12Cr 804.5Cr 12Cr 82Cr 32Cr 395.99Cr 32Cr 31Cr
Net Debt 50TCr 307.2Cr 267.85Cr 248.07Cr 232.23Cr 435.53Cr 29TCr 438.17Cr 2.94TCr 1.14TCr 14TCr 1.15TCr 1.13TCr 51TCr 316.4Cr 275.87Cr 255.5Cr 239.18Cr 448.57Cr 30TCr 451.28Cr 3.03TCr 1.17TCr 15TCr 1.19TCr 1.16TCr
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
39,168
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,647.00JPY
Average target price
1,876.00JPY
Spread / Average Target
+13.90%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!